Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 12/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 6/20 | 0.35 |
| ▸ | ACHE | P22303 | 6/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020904 | 0.84 | MEN1 (0.37) | HTR6MAPK1 | |
| SCHEMBL1019432 | 0.82 | PDE4A (0.34) | TSHR | |
| SCHEMBL1021912 | 0.80 | NOS2 (0.41) | HTR6TSHRMAPK1CYP2D6 | |
| SCHEMBL1019787 | 0.79 | CHRM2 (0.39) | CHRM2HTR6CHRM1CHRM3 | |
| SCHEMBL1020739 | 0.77 | CHRM2 (0.38) | CHRM2HTR6BCHEACHETSHR | |
| SCHEMBL1020636 | 0.77 | LMNA (0.36) | HTR6MAPK1TDP1 | |
| SCHEMBL1020900 | 0.76 | CNR2 (0.32) | HTR6 | |
| SCHEMBL13950484 | 0.76 | TAS2R14 (0.38) | TSHRTP53RECQL | |
| SCHEMBL1020376 | 0.76 | TAS2R14 (0.42) | TP53 | |
| SCHEMBL1022342 | 0.75 | CNR2 (0.33) | HTR6CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| EP-2094677-B1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | REMYND NV (BE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | CHRM2 3891/4885HTR6 2082/4885BCHE 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.